Transition begins patient dosing in phase 2 study of SARM drug candidate TT701

Transition begins patient dosing in phase 2 study of SARM drug candidate TT701

The phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency (sexual symptoms, fatigue/low vitality, and physical dysfunction) in men with prostate cancer who have undergone radical prostatectomy for …

(Visited 1 times, 1 visits today)
4
Like
Save

Comments

Write a comment

*